Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Comparison of the Effects of Desloratadine and Placebo in the Relief of Nasal Symptom Scores in Subjects With Seasonal Allergic Rhinitis to Cypress Pollen (Study P02836)
- First Posted Date
- 2009-03-23
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 233
- Registration Number
- NCT00867191
Pediatric Study to Evaluate the Efficacy and Safety of Ezetimibe Monotherapy in Children With Primary Hypercholesterolemia (P05522)
- First Posted Date
- 2009-03-23
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 138
- Registration Number
- NCT00867165
Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED)
Phase 3
Completed
- Conditions
- Cardiovascular DisorderDiabetes Mellitus
- Interventions
- First Posted Date
- 2009-03-16
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 808
- Registration Number
- NCT00862251
A Randomized Trial Assessing Once Daily Administration of Mometasone Furoate DPI in Asthmatics (Study P02177)
Phase 4
Completed
- Conditions
- Asthma
- Interventions
- Device: Mometasone furoate
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 216
- Registration Number
- NCT00835094
Assessment of Intranasal Steroids in Allergic Rhinitis When Used Alone or in Combination With an Oral Antihistamine (Study P03270)
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 72
- Registration Number
- NCT00834119
Pediatric ACTION3 (Identify, Treat, Control): Effectiveness of Adding Montelukast in Pediatric Subjects With Uncontrolled Asthma (0476-385)
- First Posted Date
- 2009-01-30
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 445
- Registration Number
- NCT00832455
Study of MK-0663/Etoricoxib in Postorthopedic Knee Replacement Surgery Pain (MK-0663-098)
Phase 3
Completed
- Conditions
- Pain, Postoperative
- Interventions
- Drug: Matching Placebo for Etoricoxib 120 mgDrug: Matching Placebo for Etoricoxib 90 mgDrug: Matching Placebo for Ibuprofen
- First Posted Date
- 2009-01-09
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 776
- Registration Number
- NCT00820027
A Study to Determine the Efficacy and Safety of Two Mometasone Dry Powder Inhalers in the Treatment of Asthma (Study P02524)
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Device: MF
- First Posted Date
- 2009-01-07
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 93
- Registration Number
- NCT00817817
Study of the Effectiveness and Safety of Desloratadine (Aerius) Syrup in Children With Allergic Skin Inflammation (P03475)
- First Posted Date
- 2009-01-06
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 40
- Registration Number
- NCT00817076
Single Dose Crossover Study of Patient Preference for Unscented Nasonex® Nasal Spray Versus Scented Flonase® Nasal Spray (Study P04207)
Phase 4
Completed
- Conditions
- Allergic Rhinitis
- Interventions
- First Posted Date
- 2009-01-06
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 100
- Registration Number
- NCT00817050